Q3 Earnings Estimate for RVMD Issued By Leerink Partnrs

Revolution Medicines, Inc. (NASDAQ:RVMD) – Equities research analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Revolution Medicines in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang anticipates that the company will earn ($1.18) per share for the quarter. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.19) EPS.

RVMD has been the topic of a number of other research reports. Piper Sandler upped their price target on Revolution Medicines from $57.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Guggenheim increased their target price on shares of Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Stifel Nicolaus dropped their price target on shares of Revolution Medicines from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Wedbush reaffirmed an “outperform” rating and issued a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, February 27th. Finally, UBS Group lifted their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Twelve research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $66.31.

Revolution Medicines Stock Down 1.0 %

NASDAQ RVMD opened at $37.96 on Monday. The company has a market capitalization of $6.39 billion, a price-to-earnings ratio of -10.57 and a beta of 1.45. Revolution Medicines has a twelve month low of $29.15 and a twelve month high of $62.40. The stock has a fifty day simple moving average of $41.91 and a 200 day simple moving average of $46.15.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11).

Insider Buying and Selling at Revolution Medicines

In related news, Director Thilo Schroeder acquired 1,304,347 shares of the stock in a transaction dated Thursday, December 5th. The stock was purchased at an average cost of $46.00 per share, with a total value of $59,999,962.00. Following the completion of the purchase, the director now directly owns 2,096,612 shares in the company, valued at $96,444,152. This trade represents a 164.64 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jack Anders sold 2,635 shares of Revolution Medicines stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $119,629.00. Following the transaction, the chief financial officer now directly owns 96,470 shares in the company, valued at approximately $4,379,738. The trade was a 2.66 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,678 shares of company stock valued at $847,981. Company insiders own 8.00% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Revolution Medicines by 14.7% in the fourth quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company’s stock valued at $747,799,000 after purchasing an additional 2,185,082 shares during the last quarter. Farallon Capital Management LLC increased its stake in Revolution Medicines by 17.1% in the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company’s stock valued at $579,498,000 after buying an additional 1,931,000 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Revolution Medicines by 54.5% during the 4th quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company’s stock worth $414,777,000 after buying an additional 3,346,755 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in shares of Revolution Medicines by 4.9% in the 4th quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company’s stock worth $347,163,000 after buying an additional 367,882 shares during the last quarter. Finally, Nextech Invest Ltd. grew its holdings in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after acquiring an additional 1,304,347 shares in the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.